Drug Trial Radar · NCT06657222
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Dec 13, 2024
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Oct 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose. Participants will: Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for checkups and tests Answer patient reported outcome questionnaires about their symptoms
Conditions
- Advanced Solid Tumors
- HNSCC
- SCLC
- NSCLC
- TNBC - Triple-Negative Breast Cancer
- CRC
Interventions
TUB-030Drug
A complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determination of MTDTime frame: From enrollment until 30 days after last study drug
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
Yale Cancer Center
New Haven, Connecticut · Recruiting
University of Miami
Miami, Florida · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Washington University
St Louis, Missouri · Recruiting
Mount Sinai
New York, New York · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
NEXT Oncology Austin
Austin, Texas · Recruiting
NEXT Oncology - Dallas
Irving, Texas · Recruiting
NEXT Oncology - San Antonio
San Antonio, Texas · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Princess Margaret
Toronto, Canada · Recruiting
Institut Curie
Paris, France · Recruiting
Institut Gustave Roussy
Villejuif, France · Not yet recruiting
Arensia Exploratory Medicine
Bucharest, Romania · Recruiting
Arensia Exploratory Medicine
Cluj-Napoca, Romania · Recruiting
Hospital Clinic Barcelona
Barcelona, Spain · Recruiting
Clinica Uni de Navara
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.